Loading NVAX detail
Loading ticker data...
Loading NVAX detail
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.
The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate.
Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Chart data unavailable
In the latest trading session, Novavax (NVAX) closed at $8.53, marking a +1.31% move from the previous day.
The investor, which holds roughly 9% of the company, argued that leadership has failed to translate Novavax's vaccine platform into meaningful commercial success.
Activist investor Shah Capital plans to vote against the re-election of board nominees and the executive compensation package at Novavax's upcoming annual meeting, renewing pressure for changes at the vaccine maker.
Novavax, Inc. (NASDAQ: NVAX - Get Free Report) saw some unusual options trading on Monday. Stock investors purchased 21,020 call options on the stock. This is an increase of approximately 71% compared to the typical daily volume of 12,273 call options. Institutional Trading of Novavax A number of large investors have recently added to or reduced
In the closing of the recent trading day, Novavax (NVAX) stood at $8.02, denoting a -1.47% move from the preceding trading day.
Novavax, Inc. (NASDAQ: NVAX - Get Free Report) crossed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $8.28 and traded as high as $8.42. Novavax shares last traded at $8.09, with a volume of 4,148,236 shares trading hands. Analyst Upgrades and Downgrades
The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical Officer Dr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D).
In the most recent trading session, Novavax (NVAX) closed at $8.95, indicating a -4.18% shift from the previous trading day.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The first severe case of the virus has been detected in New York.
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax, Inc. (NVAX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Novavax, Inc. (NVAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
